

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock code: 0460)

CHANGE IN DIRECTOR'S INFORMATION

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51(2) and 13.51B(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

On 23 December 2021, the Board was informed by Mr. Patrick Sun (“**Mr. Sun**”), an independent non-executive Director, that it has recently come to his attention that at a hearing of the Supreme Court of Bermuda held on 13 August 2021, it was ordered, among other things, that Trinity Limited (in liquidation) (“**Trinity**”) (stock code: 891) be wound up due to failure to repay its debt. Mr. Sun was an independent non-executive director of Trinity until he resigned from his positions in Trinity on 19 November 2020, after which he had not been kept informed by Trinity of its affairs. The Company understands from Mr. Sun that the petition for liquidation of Trinity commenced after his resignation.

Trinity is a limited liability company incorporated in Bermuda whose shares are listed on the main board of the Stock Exchange (stock code: 891). For further information on the nature of business of Trinity and the said hearing and order, please refer to announcements of Trinity published on the Stock Exchange's website.

This announcement is made by the Company to report the change of information in relation to Mr. Sun in compliance with the requirements of Rule 13.51B(2) of the Listing Rules. Mr. Sun confirmed that save as disclosed in this announcement, there is no other matter relating to him that is required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules and that he is not aware of any other matters that need to be brought to the attention of the shareholders of the Company.

As the winding up of Trinity did not involve the Group, the Board is of the opinion that such matter has or will have no adverse effect on the business and operations of the Group.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 24 December 2021

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.